NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.89%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.95, delivering a surprise of -97.92%.Over the last four quarters, the co ...

Company Performance - Haemonetics reported quarterly earnings of $1.24 per share, exceeding the Zacks Consensus Estimate of $1.22 per share, and up from $0.90 per share a year ago [1] - The company posted revenues of $330.6 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1%, but down from $343.29 million year-over-year [3] - The earnings surprise for this quarter was 1.64%, and Haemonetics has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Haemonetics shares have declined approximately 17.7% since the beginning of the year, compared to a decline of 4.3% for the S&P 500 [4] - The current Zacks Rank for Haemonetics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.07 on revenues of $315.05 million, and for the current fiscal year, it is $4.98 on revenues of $1.32 billion [8] - The estimate revisions trend for Haemonetics is mixed, and changes in earnings expectations may occur following the recent earnings report [5][7] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges ahead [9]

Company Performance - Core Molding Technologies (CMT) reported quarterly earnings of $0.25 per share, missing the Zacks Consensus Estimate of $0.33 per share, and down from $0.43 per share a year ago, representing an earnings surprise of -24.24% [1] - The company posted revenues of $61.45 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 10.24%, and down from $78.15 million year-over-year [2] - Over the last four quarters, CMT has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - CMT shares have declined approximately 6.8% since the beginning of the year, compared to a decline of -4.3% for the S&P 500 [3] - The current consensus EPS estimate for the coming quarter is $0.60 on revenues of $80.46 million, and for the current fiscal year, it is $1.72 on revenues of $302.57 million [7] Industry Outlook - The Rubber - Plastics industry, to which CMT belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]

Financial Performance - Novavax reported quarterly earnings of $2.93 per share, significantly exceeding the Zacks Consensus Estimate of $0.71 per share, and compared to a loss of $1.05 per share a year ago, representing an earnings surprise of 312.68% [1] - The company posted revenues of $666.66 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 215.04%, and compared to year-ago revenues of $93.86 million [2] Market Performance - Novavax shares have declined approximately 26% since the beginning of the year, while the S&P 500 has decreased by 4.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $149.29 million, and for the current fiscal year, it is $0.84 on revenues of $633.26 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Novavax belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Novavax's stock performance [5]

Core Insights - Nova Ltd. reported quarterly earnings of $2.18 per share, exceeding the Zacks Consensus Estimate of $2.08 per share, and showing a significant increase from $1.39 per share a year ago, representing an earnings surprise of 4.81% [1] - The company achieved revenues of $213.36 million for the quarter, surpassing the Zacks Consensus Estimate by 1.41%, and up from $141.8 million year-over-year [2] - Nova Ltd. has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.05 on revenues of $210.6 million, and for the current fiscal year, it is $8.30 on revenues of $840.7 million [7] Industry Context - The Electronics - Semiconductors industry, to which Nova Ltd. belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Nova Ltd.'s performance [5][6]

分组1 - Griffon reported quarterly earnings of $1.23 per share, exceeding the Zacks Consensus Estimate of $1.13 per share, but down from $1.35 per share a year ago, representing an earnings surprise of 8.85% [1] - The company posted revenues of $611.75 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.64% and down from $672.88 million year-over-year [2] - Over the last four quarters, Griffon has surpassed consensus EPS estimates three times, but has topped consensus revenue estimates only once [2] 分组2 - The stock has underperformed the market, losing about 4.7% since the beginning of the year compared to the S&P 500's decline of 4.3% [3] - The current consensus EPS estimate for the coming quarter is $1.53 on revenues of $669.26 million, and for the current fiscal year, it is $5.71 on revenues of $2.59 billion [7] - The Zacks Industry Rank indicates that the Diversified Operations industry is in the bottom 38% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Berry Petroleum (BRY) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this independent upstream energy company would post earnings of $0.12 per share when it actually produced earnings of $0.21, delivering a surprise of 75%.Over the last four q ...

分组1 - Peloton reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, and an improvement from a loss of $0.45 per share a year ago, indicating a surprise of -100% [1] - The company posted revenues of $624 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.69%, but down from $717.7 million year-over-year [2] - Peloton shares have declined approximately 19.8% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] 分组2 - The earnings outlook for Peloton is mixed, with the current consensus EPS estimate for the coming quarter at -$0.03 on revenues of $579.12 million, and -$0.36 on revenues of $2.46 billion for the current fiscal year [7] - The Leisure and Recreation Products industry, to which Peloton belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Appian (APPN) reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, compared to a loss of $0.24 per share a year ago, indicating a significant earnings surprise of 333.33% [1] - The company achieved revenues of $166.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.20% and showing an increase from $149.84 million in the same quarter last year [2] - Appian has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The sustainability of Appian's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.14 on revenues of $160.09 million, while for the current fiscal year, it is $0.17 on revenues of $676.39 million [7] Industry Context - The Internet - Software industry, to which Appian belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Appian's stock performance [5][6]

Group 1: Earnings Performance - Altice USA reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.05 per share a year ago, indicating an earnings surprise of -77.78% [1] - The company posted revenues of $2.15 billion for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.48%, and down from $2.25 billion in the same quarter last year [2] - Over the last four quarters, Altice USA has not surpassed consensus EPS estimates and has consistently missed revenue estimates [2] Group 2: Stock Performance and Outlook - Altice USA shares have increased by about 10% since the beginning of the year, contrasting with a -4.3% decline in the S&P 500 [3] - The company's earnings outlook is critical for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $2.15 billion, and -$0.30 on revenues of $8.57 billion for the current fiscal year [7] Group 3: Industry Context - The Communication - Components industry, to which Altice USA belongs, is currently ranked in the bottom 17% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Altice USA's stock performance [5] - The unfavorable trend in estimate revisions has resulted in a Zacks Rank 5 (Strong Sell) for Altice USA, suggesting expected underperformance in the near future [6]